ArticleClinics (Sao Paulo, Brazil)2026
Seroprevalence of hepatitis C antibodies in pregnant women in the state of Paraná, Brazil.
Article in Clinics (Sao Paulo, Brazil), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionHepatitis C (HCV) is an important cause of global morbidity and mortality and can progress to cirrhosis and hepatocellular carcinoma. Vertical transmission occurs in around 5%‒6% of cases, increasing in pregnant women with a high viral load or co-infection with HIV. Although universal screening is recommended by international guidelines, its implementation in Brazil is uneven. This study estimated the seroprevalence of anti-HCV antibodies among pregnant women attending public maternity hospitals in Paraná and compared the results with national data. MATERIAL AND
methodsThis was an observational, descriptive, and cross-sectional population-based study to assess seroprevalence. The study included 1202 pregnant women aged between 16 and 49, treated in 14 public maternity hospitals in Paraná, in different regions of the state. Anti-HCV screening was carried out by ELISA, and reactive cases were confirmed by viral load (PCR). Sociodemographic and obstetric data and risk factors were obtained from questionnaires and medical records.
resultsNine participants tested positive for anti-HCV antibodies, corresponding to a seroprevalence of 0.75% (95% CI 0.34%‒1.40%). This seroprevalence falls within the range reported in previous Brazilian cross-sectional studies of pregnant women (0.06%-2.66%). No active infection was identified, as all reactive samples were HCV RNA-negative. More than half were unaware of their previous infection. No significant associations with traditional risk factors were observed. DISCUSSION: The low anti-HCV seroprevalence and the absence of detectable viremia indicate a minimal risk of vertical transmission in the cohort studied. These findings are consistent with low endemicity settings and support the role of prenatal screening in identifying previously undiagnosed infection and enabling linkage to postpartum care. The studies reviewed showed substantial heterogeneity in prevalence estimates, reflecting differences in population characteristics, sample sizes, study periods, and methodologies. The under-representation of rural areas and the exclusion of illiterate women may have led to an underestimation of seroprevalence and should be considered when interpreting the results. Therefore, the findings are primarily generalizable to literate pregnant women attending public maternity hospitals in urban and peri‑urban áreas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.